Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company's stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Halozyme Therapeutics Stock Performance

HALO traded up $0.68 during trading hours on Tuesday, reaching $51.19. The company's stock had a trading volume of 1,790,205 shares, compared to its average volume of 1,471,876. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The company's 50-day moving average is $50.10 and its 200-day moving average is $54.00. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The firm has a market cap of $6.51 billion, a PE ratio of 16.95, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24.

Analyst Ratings Changes

A number of brokerages have recently commented on HALO. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Wells Fargo & Company cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. Piper Sandler upped their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a report on Monday, November 4th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, JPMorgan Chase & Co. cut Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.11.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Verdence Capital Advisors LLC boosted its stake in Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock valued at $757,000 after purchasing an additional 252 shares during the period. GAMMA Investing LLC boosted its position in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock valued at $50,000 after acquiring an additional 350 shares during the period. Private Advisor Group LLC grew its stake in shares of Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company's stock valued at $1,191,000 after acquiring an additional 412 shares in the last quarter. Juncture Wealth Strategies LLC increased its position in Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock worth $690,000 after acquiring an additional 415 shares during the period. Finally, Diversify Advisory Services LLC raised its stake in Halozyme Therapeutics by 8.5% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company's stock worth $305,000 after purchasing an additional 418 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.